Apical junction complex proteins and ulcerative colitis: a focus on the PTPRS gene

References

• Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology133(5), 1670–1689 (2007).
   PubMed Web of Science ®Google Scholar
• Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig. Liver Dis.35(12), 862–868 (2003).
   PubMedGoogle Scholar
• Jaskowski TD, Litwin CM, Hill HR. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin. Vaccine Immunol.13(6), 655–660 (2006).
   PubMedGoogle Scholar
• Kugathasan S, Werlin SL. Measurement of pANCA (antineutrophil cytoplasmic antibodies) and ASCA (anti-Saccharomyces cerevisiae) in screening for IBD in young children. Inflamm. Bowel Dis.5(4), 283–284 (1999).
   PubMedGoogle Scholar
• Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn’s disease-associated I2 sequence and T-cell superantigen. Infect. Immun.70(12), 6567–6575 (2002).
   PubMed Web of Science ®Google Scholar
• Sutton CL, Kim J, Yamane A et al. Identification of a novel bacterial sequence associated with Crohn’s disease. Gastroenterology119(1), 23–31 (2000).
   PubMedGoogle Scholar
• Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am. J. Gastroenterol.99(11), 2235–2241 (2004).
   PubMed Web of Science ®Google Scholar
• Lodes MJ, Cong Y, Elson CO et al. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest.113(9), 1296–1306 (2004).
   PubMed Web of Science ®Google Scholar
• Targan SR, Landers CJ, Yang H et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology128(7), 2020–2028 (2005).
   PubMed Web of Science ®Google Scholar
• D’Inca R, Dal Pont E, Di Leo V et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int. J. Colorectal Dis.22(4), 429–437 (2007).
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Kleinman K et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin. Gastroenterol. Hepatol.5(12), 1424–1429 (2007).
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol.3(7), 390–407 (2006).
   PubMedGoogle Scholar
• Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature411(6837), 599–603 (2001).
   PubMed Web of Science ®Google Scholar
• Rioux JD, Xavier RJ, Taylor KD et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet.39(5), 596–604 (2007).
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science314(5804), 1461–1463 (2006).
   PubMed Web of Science ®Google Scholar
• Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature447(7145), 661–678 (2007).
   PubMed Web of Science ®Google Scholar
• Muise AM, Walters T, Wine E et al. Protein-tyrosine phosphatase σ is associated with ulcerative colitis. Curr. Biol.17(14), 1212–1218 (2007).
   PubMedGoogle Scholar
• Daly MJ, Pearce AV, Farwell L et al. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur. J. Hum. Genet.13(7), 835–839 (2005).
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature411(6837), 603–606 (2001).
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem.278(11), 8869–8872 (2003).
   PubMed Web of Science ®Google Scholar
• Maeda S, Hsu LC, Liu H et al. Nod2 mutation in Crohn’s disease potentiates NF-kB activity and IL-1β processing. Science307(5710), 734–738 (2005).
   PubMed Web of Science ®Google Scholar
• Ogura Y, Lala S, Xin W et al. Expression of NOD2 in Paneth cells: a possible link to Crohn’s ileitis. Gut52(11), 1591–1597 (2003).
   PubMed Web of Science ®Google Scholar
• Lala S, Ogura Y, Osborne C et al. Crohn’s disease and the NOD2 gene: a role for paneth cells. Gastroenterology125(1), 47–57 (2003).
   PubMed Web of Science ®Google Scholar
• Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a metaanalysis. Am. J. Gastroenterol.99(12), 2393–2404 (2004).
   PubMed Web of Science ®Google Scholar
• Hugot JP. CARD15/NOD2 mutations in Crohn’s disease. Ann. NY Acad. Sci.1072, 9–18 (2006).
   PubMed Web of Science ®Google Scholar
• Peltekova VD, Wintle RF, Rubin LA et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat. Genet.36(5), 471–475 (2004).
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Duerr RH, Brant SR et al. Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn’s disease. Eur. J. Hum. Genet.15(3), 328–335 (2007).
   PubMedGoogle Scholar
• Stoll M, Corneliussen B, Costello CM et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat. Genet.36(5), 476–480 (2004).
   PubMed Web of Science ®Google Scholar
• Brant SR, Panhuysen CI, Nicolae D et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet.73(6), 1282–1292 (2003).
   PubMed Web of Science ®Google Scholar
• Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J. Gastroenterol.12(23), 3636–3644 (2006).
   PubMed Web of Science ®Google Scholar
• Wilk JN, Bilsborough J, Viney JL. The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease. Immunol. Res.31(2), 151–159 (2005).
   PubMed Web of Science ®Google Scholar
• Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, Gale JD. Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br. J. Pharmacol.143(5), 590–598 (2004).
   PubMed Web of Science ®Google Scholar
• Franke A, Hampe J, Rosenstiel P et al. Systematic association mapping identifies NELL1 as a novel IBD disease gene. PLoS ONE2, E691 (2007).
   PubMed Web of Science ®Google Scholar
• Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet.39(2), 207–211 (2007).
   PubMed Web of Science ®Google Scholar
• Libioulle C, Louis E, Hansoul S et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet.3(4), E58 (2007).
   PubMed Web of Science ®Google Scholar
• Parkes M, Barrett JC, Prescott NJ et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat. Genet.39(7), 830–832 (2007).
   PubMed Web of Science ®Google Scholar
• Raelson JV, Little RD, Ruether A et al. Genome-wide association study for Crohn’s disease in the Quebec Founder Population identifies multiple validated disease loci. Proc. Natl Acad. Sci. USA104(37), 14747–14752 (2007).
   PubMed Web of Science ®Google Scholar
• Yamazaki K, McGovern D, Ragoussis J et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn’s disease. Hum. Mol. Genet.14(22), 3499–3506 (2005).
   PubMed Web of Science ®Google Scholar
• Tremelling M, Cummings F, Fisher SA et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology132(5), 1657–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata A. Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn’s disease in Japanese patients. J. Hum. Genet.52(7), 575–583 (2007).
   PubMed Web of Science ®Google Scholar
• Burton PR, Clayton DG, Cardon LR et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet.39(11), 1329–1337 (2007).
   PubMed Web of Science ®Google Scholar
• Begovich AB, Chang M, Caillier SJ et al. The autoimmune disease-associated IL12B and IL23R polymorphisms in multiple sclerosis. Hum. Immunol.68(11), 934–937 (2007).
   PubMed Web of Science ®Google Scholar
• McGovern D, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut56(10), 1333–1336 (2007).
   PubMed Web of Science ®Google Scholar
• Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science313(5792), 1438–1441 (2006).
   PubMed Web of Science ®Google Scholar
• Meddings J. Barrier dysfunction and Crohn’s disease. Ann. NY Acad. Sci.915, 333–338 (2000).
   PubMed Web of Science ®Google Scholar
• Hollander D. Crohn’s disease – a permeability disorder of the tight junction? Gut29(12), 1621–1624 (1988).
   PubMed Web of Science ®Google Scholar
• Weber CR, Turner JR. Inflammatory bowel disease: is it really just another break in the wall? Gut56(1), 6–8 (2007).
   PubMed Web of Science ®Google Scholar
• Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut55(10), 1512–1520 (2006).
   PubMed Web of Science ®Google Scholar
• Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand. J. Gastroenterol.35(11), 1163–1169 (2000).
   PubMedGoogle Scholar
• Wyatt J, Oberhuber G, Pongratz S et al. Increased gastric and intestinal permeability in patients with Crohn’s disease. Am. J. Gastroenterol.92(10), 1891–1896 (1997).
   PubMed Web of Science ®Google Scholar
• Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet341(8858), 1437–1439 (1993).
   PubMed Web of Science ®Google Scholar
• Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr. Opin. Gastroenterol.23(4), 379–383 (2007).
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn’s disease in a subject with familial risk. Gastroenterology119(6), 1740–1744 (2000).
   PubMed Web of Science ®Google Scholar
• May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn’s disease? Gastroenterology104(6), 1627–1632 (1993).
   PubMed Web of Science ®Google Scholar
• Ivanov AI, Nusrat A, Parkos CA. The epithelium in inflammatory bowel disease: potential role of endocytosis of junctional proteins in barrier disruption. Novartis Found. Symp.263, 115–124; discussion 24–32, 211–218 (2004).
   PubMedGoogle Scholar
• Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science270(5239), 1203–1207 (1995).
   PubMed Web of Science ®Google Scholar
• Bruewer M, Samarin S, Nusrat A. Inflammatory bowel disease and the apical junctional complex. Ann. NY Acad. Sci.1072, 242–252 (2006).
   PubMed Web of Science ®Google Scholar
• Buhner S, Buning C, Genschel J et al. Genetic basis for increased intestinal permeability in families with Crohn’s disease: role of CARD15 3020insC mutation? Gut55(3), 342–347 (2006).
   PubMed Web of Science ®Google Scholar
• Hugot JP, Zaccaria I, Cavanaugh J et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am. J. Gastroenterol.102(6), 1259–1267 (2007).
   PubMed Web of Science ®Google Scholar
• Wapenaar MC, Monsuur A, van Bodegraven A et al. Associations with tight junction genes PARD3 and Magi2 in Dutch patients point to a common barrier defect for celiac disease and ulcerative colitis. Gut57, 463–467 (2008).
   PubMed Web of Science ®Google Scholar
• Wolters VM, Verbeek WH, Zhernakova A et al. The MYO9B gene is a strong risk factor for developing refractory celiac disease. Clin. Gastroenterol. Hepatol.5(12), 1399–1405 (2007).
   PubMed Web of Science ®Google Scholar
• Monsuur AJ, de Bakker PI, Alizadeh BZ et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat. Genet.37(12), 1341–1344 (2005).
   PubMed Web of Science ®Google Scholar
• Latiano A, Palmieri O, Valvano MR et al. The association of MYO9B gene in Italian patients with inflammatory bowel diseases. Aliment. Pharmacol. Ther.27(3), 241–248 (2008).
   PubMed Web of Science ®Google Scholar
• van Bodegraven AA, Curley CR, Hunt KA et al. Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology131(6), 1768–1774 (2006).
   PubMed Web of Science ®Google Scholar
• Nunez C, Oliver J, Mendoza JL et al. MYO9B polymorphisms in patients with inflammatory bowel disease. Gut56(9), 1321–1322 (2007).
   PubMed Web of Science ®Google Scholar
• van den Boom F, Dussmann H, Uhlenbrock K, Abouhamed M, Bahler M. The myosin IXb motor activity targets the myosin IXb RhoGAP domain as cargo to sites of actin polymerization. Mol. Biol. Cell.18(4), 1507–1518 (2007).
   PubMedGoogle Scholar
• Hirose T, Izumi Y, Nagashima Y et al. Involvement of ASIP/PAR-3 in the promotion of epithelial tight junction formation. J. Cell Sci.115(Pt 12), 2485–2495 (2002).
   PubMed Web of Science ®Google Scholar
• Chen X, Macara IG. Par-3 controls tight junction assembly through the Rac exchange factor Tiam1. Nat. Cell Biol.7(3), 262–269 (2005).
   PubMed Web of Science ®Google Scholar
• Chen X, Macara IG. Par-3 mediates the inhibition of LIM kinase 2 to regulate cofilin phosphorylation and tight junction assembly. J. Cell Biol.172(5), 671–678 (2006).
   PubMedGoogle Scholar
• Wang X, Nie J, Zhou Q et al. Downregulation of Par-3 expression and disruption of Par complex integrity by TGF-β during the process of epithelial to mesenchymal transition in rat proximal epithelial cells. Biochim. Biophys. Acta1782(1), 51–59 (2008).
   PubMedGoogle Scholar
• Kawajiri A, Itoh N, Fukata M et al. Identification of a novel β-catenin-interacting protein. Biochem. Biophys. Res. Commun.273(2), 712–717 (2000).
   PubMedGoogle Scholar
• Subauste MC, Nalbant P, Adamson ED, Hahn KM. Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein β-catenin with the scaffolding protein MAGI-2. J. Biol. Chem.280(7), 5676–56781 (2005).
   PubMed Web of Science ®Google Scholar
• Nechiporuk T, Fernandez TE, Vasioukhin V. Failure of epithelial tube maintenance causes hydrocephalus and renal cysts in Dlg5-/- mice. Dev. Cell13(3), 338–350 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch KW, Weiss A. A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J. Biol. Chem.276(26), 24341–24347 (2001).
   PubMedGoogle Scholar
• Mustelin T, Tautz L, Page R. Structure of the hematopoietic tyrosine phosphatase (HePTP) catalytic domain: structure of a KIM phosphatase with phosphate bound at the active site. J. Mol. Biol.354(1), 150–163 (2005).
   PubMedGoogle Scholar
• Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol.7(11), 833–846 (2006).
   PubMed Web of Science ®Google Scholar
• Chagnon MJ, Uetani N, Tremblay ML. Functional significance of the LAR receptor protein tyrosine phosphatase family in development and diseases. Biochem. Cell Biol.82(6), 664–675 (2004).
   PubMedGoogle Scholar
• Bueno OF, De Windt LJ, Lim HW et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vitro. Circ. Res.88(1), 88–96 (2001).
   PubMedGoogle Scholar
• Dominguez MG, Hughes VC, Pan L et al. Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis. Proc. Natl Acad. Sci. USA104(9), 3243–3248 (2007).
   PubMedGoogle Scholar
• Snyder EM, Nong Y, Almeida CG et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci.8(8), 1051–1058 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobsen M, Schweer D, Ziegler A et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat. Genet.26(4), 495–499 (2000).
   PubMed Web of Science ®Google Scholar
• Fujikawa A, Shirasaka D, Yamamoto S et al. Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat. Genet.33(3), 375–381 (2003).
   PubMed Web of Science ®Google Scholar
• Li L, Dixon JE. Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases. Semin. Immunol.12(1), 75–84 (2000).
   PubMed Web of Science ®Google Scholar
• Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol.18(4), 207–213 (2006).
   PubMed Web of Science ®Google Scholar
• Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, Mustelin T. Protein tyrosine phosphatases in autoimmunity. Annu. Rev. Immunol.26, 29–55 (2008).
   PubMed Web of Science ®Google Scholar
• Vang T, Congia M, Macis MD et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet.37(12), 1317–1319 (2005).
   PubMed Web of Science ®Google Scholar
• You-Ten KE, Muise ES, Itie A et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med.186(5), 683–693 (1997).
   PubMed Web of Science ®Google Scholar
• Zhu W, Mustelin T, David M. Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase. J. Biol. Chem.277(39), 35787–35790 (2002).
   PubMedGoogle Scholar
• Ogata T, Yoshida R. PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes. Pediatr. Endocrinol. Rev.2(4), 669–674 (2005).
   PubMedGoogle Scholar
• Wang Z, Shen D, Parsons DW et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science304(5674), 1164–1166 (2004).
   PubMed Web of Science ®Google Scholar
• Wu CW, Kao HL, Li AF, Chi CW, Lin WC. Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. Cancer Lett.242(1), 95–103 (2006).
   PubMedGoogle Scholar
• Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer6(4), 307–320 (2006).
   PubMed Web of Science ®Google Scholar
• MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol.7(6), 591–600 (2005).
   PubMed Web of Science ®Google Scholar
• Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin. Cancer Res.9(1), 68–75 (2003).
   PubMed Web of Science ®Google Scholar
• Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood100(10), 3553–3560 (2002).
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Okamoto A, Matsufuji S. A commonly deleted region in ovarian cancer on chromosome 19p13.3, not including the OAZ1 gene. Int. J. Oncol.23(3), 567–575 (2003).
   PubMedGoogle Scholar
• Yap YL, Zhang XW, Smith D, Soong R, Hill J. Molecular gene expression signature patterns for gastric cancer diagnosis. Comput. Biol. Chem.31(4), 275–287 (2007).
   PubMedGoogle Scholar
• Lepourcelet M, Tou L, Cai L et al. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development132(2), 415–427 (2005).
   PubMedGoogle Scholar
• Miscio G, Tassi V, Coco A et al. The allelic variant of LAR gene promoter -127 bp T→A is associated with reduced risk of obesity and other features related to insulin resistance. J. Mol. Med.82(7), 459–466 (2004).
   PubMedGoogle Scholar
• Langberg EC, Gu HF, Nordman S, Efendic S, Ostenson CG. Genetic variation in receptor protein tyrosine phosphatise s is associated with type 2 diabetes in Swedish Caucasians. Eur. J. Endocrinol.157(4), 459–464 (2007).
   PubMedGoogle Scholar
• Doney AS, Fischer B, Cecil JE et al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia47(3), 555–558 (2004).
   PubMed Web of Science ®Google Scholar
• Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-a gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes56(4), 1181–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Sugawara K, Olson TS, Moskaluk CA et al. Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn’s disease. Gastroenterology128(2), 351–360 (2005).
   PubMed Web of Science ®Google Scholar
• Pan MG, Rim C, Lu KP, Florio T, Stork PJ. Cloning and expression of two structurally distinct receptor-linked protein-tyrosine phosphatases generated by RNA processing from a single gene. J. Biol. Chem.268(26), 19284–19291 (1993).
   PubMedGoogle Scholar
• Walton KM, Martell KJ, Kwak SP, Dixon JE, Largent BL. A novel receptor-type protein tyrosine phosphatase is expressed during neurogenesis in the olfactory neuroepithelium. Neuron11(2), 387–400 (1993).
   PubMedGoogle Scholar
• Yan H, Grossman A, Wang H et al. A novel receptor tyrosine phosphatase-σ that is highly expressed in the nervous system. J. Biol. Chem.268(33), 24880–24886 (1993).
   PubMed Web of Science ®Google Scholar
• Stoker AW. Isoforms of a novel cell adhesion molecule-like protein tyrosine phosphatase are implicated in neural development. Mech. Dev.46(3), 201–217 (1994).
   PubMedGoogle Scholar
• Wagner J, Boerboom D, Tremblay ML. Molecular cloning and tissue-specific RNA processing of a murine receptor-type protein tyrosine phosphatase. Eur. J. Biochem.226(3), 773–782 (1994).
   PubMedGoogle Scholar
• Zhang WR, Hashimoto N, Ahmad F, Ding W, Goldstein BJ. Molecular cloning and expression of a unique receptor-like protein-tyrosine-phosphatase in the leucocyte-common-antigen-related phosphate family. Biochem. J.302(Pt 1), 39–47 (1994).
   PubMedGoogle Scholar
• Sahin M, Dowling JJ, Hockfield S. Seven protein tyrosine phosphatases are differentially expressed in the developing rat brain. J. Comp. Neurol.351(4), 617–631 (1995).
   PubMedGoogle Scholar
• Streuli M, Krueger NX, Hall LR, Schlossman SF, Saito H. A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen. J. Exp. Med.168(5), 1523–1530 (1988).
   PubMedGoogle Scholar
• Krueger NX, Streuli M, Saito H. Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. EMBO J.9(10), 3241–3252 (1990).
   PubMedGoogle Scholar
• Mizuno K, Hasegawa K, Katagiri T, Ogimoto M, Ichikawa T, Yakura H. MPTP δ, a putative murine homolog of HPTP δ, is expressed in specialized regions of the brain and in the B-cell lineage. Mol. Cell Biol.13(9), 5513–5523 (1993).
   PubMedGoogle Scholar
• Streuli M, Krueger NX, Ariniello PD et al. Expression of the receptor-linked protein tyrosine phosphatase LAR: proteolytic cleavage and shedding of the CAM-like extracellular region. EMBO J.11(3), 897–907 (1992).
   PubMedGoogle Scholar
• O’Grady P, Krueger NX, Streuli M, Saito H. Genomic organization of the human LAR protein tyrosine phosphatase gene and alternative splicing in the extracellular fibronectin type-III domains. J. Biol. Chem.269(40), 25193–25199 (1994).
   PubMedGoogle Scholar
• Serra-Pages C, Saito H, Streuli M. Mutational analysis of proprotein processing, subunit association, and shedding of the LAR transmembrane protein tyrosine phosphatase. J. Biol. Chem.269(38), 23632–23641 (1994).
   PubMedGoogle Scholar
• Zhang JS, Longo FM. LAR tyrosine phosphatase receptor: alternative splicing is preferential to the nervous system, coordinated with cell growth and generates novel isoforms containing extensive CAG repeats. J. Cell Biol.128(3), 415–431 (1995).
   PubMedGoogle Scholar
• Rotin D, Goldstein BJ, Fladd CA. Expression of the tyrosine phosphatase LAR-PTP2 is developmentally regulated in lung epithelia. Am. J. Physiol.267(3 Pt 1), L263–L270 (1994).
   Google Scholar
• Aricescu AR, McKinnell IW, Halfter W, Stoker AW. Heparan sulfate proteoglycans are ligands for receptor protein tyrosine phosphatase σ. Mol. Cell Biol.22(6), 1881–1892 (2002).
   PubMed Web of Science ®Google Scholar
• Sajnani-Perez G, Chilton JK, Aricescu AR, Haj F, Stoker AW. Isoform-specific binding of the tyrosine phosphatase PTPσ to a ligand in developing muscle. Mol. Cell Neurosci.22(1), 37–48 (2003).
   PubMedGoogle Scholar
• Alete DE, Weeks ME, Hovanession AG, Hawadle M, Stoker AW. Cell surface nucleolin on developing muscle is a potential ligand for the axonal receptor protein tyrosine phosphatase-σ. FEBS J.273(20), 4668–4681 (2006).
   PubMedGoogle Scholar
• Lee S, Faux C, Nixon J et al. Dimerization of ptpσ governs both ligand binding and isoform specificity. Mol. Cell Biol.27(5), 1795–1808 (2007).
   PubMedGoogle Scholar
• Neel BG, Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr. Opin. Cell Biol.9(2), 193–204 (1997).
   PubMed Web of Science ®Google Scholar
• Petrone A, Sap J. Emerging issues in receptor protein tyrosine phosphatase function: lifting fog or simply shifting? J. Cell Sci.113(Pt13), 2345–2354 (2000).
   PubMedGoogle Scholar
• Johnson KG, Van Vactor D. Receptor protein tyrosine phosphatases in nervous system development. Physiol. Rev.83(1), 1–24 (2003).
   PubMedGoogle Scholar
• Wills Z, Bateman J, Korey CA, Comer A, Van Vactor D. The tyrosine kinase Abl and its substrate enabled collaborate with the receptor phosphatase Dlar to control motor axon guidance. Neuron22(2), 301–312 (1999).
   PubMedGoogle Scholar
• Serra-Pages C, Medley QG, Tang M, Hart A, Streuli M. Liprins, a family of LAR transmembrane protein-tyrosine phosphatase-interacting proteins. J. Biol. Chem.273(25), 15611–15620 (1998).
   PubMed Web of Science ®Google Scholar
• Serra-Pages C, Kedersha NL, Fazikas L, Medley Q, Debant A, Streuli M. The LAR transmembrane protein tyrosine phosphatase and a coiled-coil LAR-interacting protein co-localize at focal adhesions. EMBO J.14(12), 2827–2838 (1995).
   PubMedGoogle Scholar
• Pulido R, Serra-Pages C, Tang M, Streuli M. The LAR/PTPδ/PTPσ subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTPδ, and PTPσ isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1. Proc. Natl Acad. Sci. USA92(25), 11686–11690 (1995).
   PubMed Web of Science ®Google Scholar
• Debant A, Serra-Pages C, Seipel K et al. The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Proc. Natl Acad. Sci. USA93(11), 5466–5471 (1996).
   PubMed Web of Science ®Google Scholar
• Kokel M, Borland CZ, DeLong L, Horvitz HR, Stern MJ. clr-1 encodes a receptor tyrosine phosphatase that negatively regulates an FGF receptor signaling pathway in Caenorhabditis elegans. Genes Dev.12(10), 1425–1437 (1998).
   PubMed Web of Science ®Google Scholar
• Faux C, Hawadle M, Nixon J et al. PTPσ binds and dephosphorylates neurotrophin receptors and can suppress NGF-dependent neurite outgrowth from sensory neurons. Biochim. Biophys. Acta1773(11), 1689–1700 (2007).
   PubMed Web of Science ®Google Scholar
• Siu R, Fladd C, Rotin D. N-cadherin is an in vivo substrate for protein tyrosine phosphatase σ (PTPσ) and participates in PTPσ-mediated inhibition of axon growth. Mol. Cell Biol.27(1), 208–219 (2007).
   PubMedGoogle Scholar
• Wallace MJ, Batt J, Fladd CA, Henderson JT, Skarnes W, Rotin D. Neuronal defects and posterior pituitary hypoplasia in mice lacking the receptor tyrosine phosphatase PTPσ. Nat. Genet.21(3), 334–338 (1999).
   PubMedGoogle Scholar
• Elchebly M, Wagner J, Kennedy TE et al. Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase σ. Nat. Genet.21(3), 330–333 (1999).
   PubMedGoogle Scholar
• Batt J, Asa S, Fladd C, Rotin D. Pituitary, pancreatic and gut neuroendocrine defects in protein tyrosine phosphatase-s-deficient mice. Mol. Endocrinol.16(1), 155–169 (2002).
   PubMedGoogle Scholar
• Wagner J, Gordon LA, Heng HH, Tremblay ML, Olsen AS. Physical mapping of receptor type protein tyrosine phosphatase σ (PTPRS) to human chromosome 19p13.3. Genomics38(1), 76–78 (1996).
   PubMedGoogle Scholar
• Rioux JD, Silverberg MS, Daly MJ et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am. J. Hum. Genet.66(6), 1863–1870 (2000).
   PubMed Web of Science ®Google Scholar
• The International HapMap Project. Nature426(6968), 789–796 (2003).
   PubMed Web of Science ®Google Scholar
• Altshuler D, Daly M. Guilt beyond a reasonable doubt. Nat. Genet.39(7), 813–815 (2007).
   PubMed Web of Science ®Google Scholar
• Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A. Human protein tyrosine phosphatase-σ: alternative splicing and inhibition by bisphosphonates. J. Bone Miner. Res.11(4), 535–543 (1996).
   PubMed Web of Science ®Google Scholar
• Lajus S, Lang J. Splice variant 3, but not 2 of receptor protein-tyrosine phosphatase σ can mediate stimulation of insulin-secretion by α-latrotoxin. J. Cell Biochem.98(6), 1552–5159 (2006).
   PubMedGoogle Scholar
• Seksik P, Sokol H, Lepage P et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment. Pharmacol. Ther.24(Suppl. 3), 11–18 (2006).
   PubMed Web of Science ®Google Scholar
• Gibson PR. Apoptosis or necrosis – colonic epithelial cell survival. Novartis Found. Symp.263, 133–145; discussion 45–50, 211–218 (2004).
   PubMedGoogle Scholar
• Fouquet S, Lugo-Martinez VH, Faussat AM et al. Early loss of E-cadherin from cell–cell contacts is involved in the onset of Anoikis in enterocytes. J. Biol. Chem.279(41), 43061–43069 (2004).
   PubMedGoogle Scholar
• Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of β-catenin. Curr. Opin. Cell Biol.17(5), 459–465 (2005).
   PubMed Web of Science ®Google Scholar
• Daniel JM, Reynolds AB. Tyrosine phosphorylation and cadherin/catenin function. Bioessays19(10), 883–891 (1997).
   PubMed Web of Science ®Google Scholar
• Matsuyoshi N, Hamaguchi M, Taniguchi S, Nagafuchi A, Tsukita S, Takeichi M. Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J. Cell Biol.118(3), 703–714 (1992).
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, Nagai Y. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J.12(1), 307–314 (1993).
   PubMed Web of Science ®Google Scholar
• Volberg T, Zick Y, Dror R et al. The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J.11(5), 1733–1742 (1992).
   PubMed Web of Science ®Google Scholar
• Brady-Kalnay SM, Mourton T, Nixon JP et al. Dynamic interaction of PTPmu with multiple cadherins in vitro. J. Cell Biol.141(1), 287–296 (1998).
   PubMed Web of Science ®Google Scholar
• Aicher B, Lerch MM, Muller T, Schilling J, Ullrich A. Cellular redistribution of protein tyrosine phosphatases LAR and PTPσ by inducible proteolytic processing. J. Cell Biol.138(3), 681–696 (1997).
   PubMed Web of Science ®Google Scholar
• Rioux JD, Daly MJ, Silverberg MS et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet.29(2), 223–228 (2001).
   PubMed Web of Science ®Google Scholar
• Kurz T, Hoffjan S, Hayes MG et al. Fine mapping and positional candidate studies on chromosome 5p13 identify multiple asthma susceptibility loci. J. Allergy Clin. Immunol.118(2), 396–402 (2006).
   PubMed Web of Science ®Google Scholar
• Beckly JB, Hancock L, Geremia A et al. Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn’s disease. Inflamm. Bowel Dis. (2008).
   Google Scholar
• De Jager PL, Franchimont D, Waliszewska A et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun.8(5), 387–397 (2007).
   PubMedGoogle Scholar
• Ferreira AC, Almeida S, Tavares M et al. NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn’s disease. Inflamm. Bowel Dis.11(4), 331–339 (2005).
   PubMed Web of Science ®Google Scholar
• Karban AS, Okazaki T, Panhuysen CI et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum. Mol. Genet.13(1), 35–45 (2004).
   PubMed Web of Science ®Google Scholar
• Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, Cho JH. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn’s disease. Am. J. Physiol. Gastrointest. Liver Physiol.290(6), G1157–G1163 (2006).
   PubMed Web of Science ®Google Scholar
• Hume GE, Fowler EV, Lincoln D et al. Angiotensinogen and transforming growth factor β1: novel genes in the pathogenesis of Crohn’s disease. J. Med. Genet.43(10), E51 (2006).
   Google Scholar
• De Iudicibus S, Stocco G, Martelossi S et al. Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease. Gut56(9), 1319–1320 (2007).
   PubMed Web of Science ®Google Scholar
• Oliver J, Marquez A, Gomez-Garcia M et al. Association of the macrophage migration inhibitory factor gene polymorphisms with inflammatory bowel disease. Gut56(1), 150–151 (2007).
   PubMedGoogle Scholar
• McGovern DP, Hysi P, Ahmad T et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum. Mol. Genet.14(10), 1245–1250 (2005).
   PubMed Web of Science ®Google Scholar
• McGovern DP, Butler H, Ahmad T et al. TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology131(4), 1190–1196 (2006).
   PubMed Web of Science ®Google Scholar
• Futami S, Aoyama N, Honsako Y et al. HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression. Dig. Dis. Sci.40(4), 814–818 (1995).
   PubMedGoogle Scholar
• Mochida A, Kinouchi Y, Negoro K et al. Butyrophilin-like 2 gene is associated with ulcerative colitis in the Japanese under strong linkage disequilibrium with HLA-DRB1*1502. Tissue Antigens70(2), 128–135 (2007).
   PubMedGoogle Scholar
• Arisawa T, Tahara T, Shibata T et al. The influence of polymorphisms of interleukin-17a and interleukin-17f genes on the susceptibility to ulcerative colitis. J. Clin. Immunol.28(1), 44–49 (2008).
   PubMed Web of Science ®Google Scholar
• Peng Z, Hu P, Cui Y, Li C. [Interleukin (IL)-1β, IL-1 receptor antagonist and IL-4 gene polymorphisms in ulcerative colitis in the Chinese]. Zhonghua Nei Ke Za Zhi41(4), 248–251 (2002).
   PubMedGoogle Scholar
• Klein W, Tromm A, Griga T et al. A polymorphism in the IL11 gene is associated with ulcerative colitis. Genes Immun.3(8), 494–496 (2002).
   PubMed Web of Science ®Google Scholar
• Obana N, Takahashi S, Kinouchi Y et al. Ulcerative colitis is associated with a promoter polymorphism of lipopolysaccharide receptor gene, CD14. Scand. J. Gastroenterol.37(6), 699–704 (2002).
   PubMed Web of Science ®Google Scholar